Aimed Alliance Comments on 2027 NBPP
On March 13, 2026, Aimed Alliance commented on the 2027 Notice of Benefit and Payment Parameters (2027 NBPP). In its…
Browsing: Aimed Activity
Aimed Alliance Provides Testimony of UPLs Before New Jersey’s PDAC
On March 19, 2026, Aimed Alliance provided testimony to the New Jersey Prescription Drug Affordability Council, which is developing legislative…
Aimed Alliance Submits Comment on FTC’s Proposed Settlement with Express Scripts
On March 16, Aimed Alliance submitted a comment on the proposed settlement between the Federal Trade Commission and Express Scripts,…
Aimed Alliance Pushes Back on PDAB Legislation in Illinois
On March 18, 2026, Aimed Alliance submitted comments to the Health Care Availability & Accessibility Committee urging caution against Illinois…
Aimed Alliance Urges Amendments to Virginia’s PDAB Bill to Protect Patient Access
On March 13, 2026, Aimed Alliance sent a letter to Governor Abigail Spanberger urging amendments to Virginia’s House Bill 483,…
Administration Targets Foreign Drug Pricing in Upcoming Section 301 Investigation
Recently, the Trump Administration announced plans to initiate a new Section 301 investigation into foreign drug pricing policies, which it…
Aimed Alliance Supports CA Copay Accumulator Ban
Aimed Alliance recently sent a letter to the California legislature urging for the ban of copay accumulator programs. These programs…
FDA Confirms AFPs Not Permissible Under Section 804
On August, 28, 2024, Aimed Alliance received an interim response from the Food and Drug Administration regarding its Citizen Petition on…
Aimed Alliance Urges Maryland PDAB to Protect Patient Access in UPL Deliberations
Aimed Alliance sent letters to the Maryland PDAB urging it to proceed cautiously with setting a UPL for Jardiance and…
New Report – International Reference Pricing: Lessons Learned from Abroad
For decades, rising costs of health care, health insurance, and prescription drugs have been a major concern for American consumers, caregivers,…